

PATENT APPLICATION TRANSMITTAL LETTER
(Large Entity)

Docket No.
1038-1026 MIS:jb

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Transmitted herewith for filing under 35 U.S.C. 111 and 37 C.F.R. 1.53 is the patent application of:

Sheena M. Loosmore; and Yan-Ping Yang

For: **CO-EXPRESSION OF RECOMBINANT PROTEINS**

Enclosed are:

- ☐ Certificate of Mailing with Express Mail Mailing Label No.
- ☒ **Twenty-six (26)** sheets of drawings.
- ☐ A certified copy of a _____ application.
- ☒ Declaration ☐ Signed. ☒ Unsigned.
- ☐ Power of Attorney
- ☐ Information Disclosure Statement
- ☐ Preliminary Amendment
- ☐ Other:

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	43	- 20 =	23	x \$18.00	\$414.00
Indep. Claims	5	- 3 =	2	x \$78.00	\$156.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$690.00
TOTAL FILING FEE					\$1,260.00


- ☒ A check in the amount of **\$1,260.00** to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. **19-2253** as described below. A duplicate copy of this sheet is enclosed.
 - ☐ Charge the amount of _____ as filing fee.
 - ☒ Credit any overpayment.
 - ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
 - ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: **24 May 2000**



24223

PATENT TRADEMARK OFFICE


Signature
Michael I. Stewart (24,973)

CC:

TITLE OF THE INVENTION
CO-EXPRESSION OF RECOMBINANT PROTEINS

FIELD OF THE INVENTION

The present invention relates to the fields of molecular biology, biochemistry
5 and vaccinology, in particular, to the co-expression of recombinant proteins.

BACKGROUND TO THE INVENTION

Recombinant proteins expressed from *E. coli*, are often made as insoluble
inclusion bodies. While the purification of inclusion bodies is relatively
straightforward and can lead to a >90% purification of the recombinant protein, the
10 resulting protein is often denatured and may be biologically inactive. In some
instances, it may be advantageous to overproduce a recombinant protein in a soluble
form. Recombinant proteins can also be degraded by host proteases. Expression of
recombinant proteins in the presence of particular proteins, such as potential molecular
chaperones, may have the effect of protecting them from degradation and ensure
15 correct folding. In other instances, it may be useful to produce two vaccine
components, from different organisms, in the same production cycle. Co-expression
of recombinant proteins encoded on genes from multiple organisms can lead to
improved production time and costs.

Otitis media is the most common illness of early childhood, with 60 to 70% of
20 all children of less than 2 years of age experiencing between one and three ear
infections (ref. 1, various references are referred to in parenthesis to more fully
describe the state of the art to which this invention pertains. Full bibliographic
information for each citation is found at the end of the specification, immediately
preceding the claims. The disclosure of these references are hereby incorporated by
25 reference into the present disclosure). Chronic otitis media is responsible for hearing,
speech and cognitive impairments in children. In the United States alone, treatment of
otitis media costs between 1 and 2 billion dollars per year for antibiotics and surgical
procedures, such as tonsillectomies, adenoidectomies and the insertion of
tympanostomy tubes. It is estimated that an additional \$30 billion is spent per annum
30 on adjunct therapies, such as speech therapy and special education classes. The
disease is caused by bacterial and/or viral infections, and many of the bacteria are

becoming antibiotic resistant. Infection with *Streptococcus pneumoniae* accounts for about 50% of bacterial disease, while non-typeable *Haemophilus influenzae* (NTHi) infections account for about 30%, and *Moraxella catarrhalis* is responsible for about 20% of acute otitis media. An effective prophylactic vaccine against otitis media is thus desirable.

When under environmental stress, such as high temperature, organisms overproduce stress response or heat shock proteins (hsps). In some instances, hsps have also been demonstrated to be molecular chaperones (ref. 2). The bacterial HtrA or DegP heat shock proteins are expressed under conditions of stress and the *H. influenzae* HtrA protein has been shown to be a partially protective antigen in the intrabulla challenge model of otitis media (ref. 3). The HtrA proteins are serine proteases and their proteolytic activity makes them unstable. In addition, as components of a multi-component vaccine, the wild-type HtrA protein degrade admixed antigens. The site-directed mutagenesis of the *H. influenzae htrA* gene (termed *hin47*) and the properties of the mutants have been fully described in U.S. Patent No. 5,506,139 (Loosmore et al.), assigned to the assignee hereof and the disclosure of which is incorporated herein by reference. The non-proteolytic HtrA analogue, H91A Hin47, has been shown to be a protective antigen in the intrabulla chinchilla model of otitis media (ref. 3). The mature H91A Hin47 protein is produced at 40 to 50% of total *E. coli* protein, in a soluble form. It may also be produced with its leader sequence, at a level of 20 to 30% of total *E. coli* protein. In this form, it may function as a molecular chaperone, anchored in the periplasmic membrane (ref. 4).

During natural infection by NTHi, surface-exposed outer membrane proteins that stimulate an antibody response are potentially important targets for bactericidal and/or protective antibodies and are therefore potential vaccine candidates. Barenkamp and Bodor (ref. 5) demonstrated that convalescent sera from children suffering from otitis media due to NTHi, contained antibodies to high molecular weight (HMW) proteins. About 70 to 75% of NTHi strains express the HMW proteins, and most of these strains contain two gene clusters termed *hmw1ABC* and *hmw2ABC* (refs. 6, 7). The HMWA proteins have been demonstrated to be adhesins mediating attachment to human epithelial cells (ref. 8). Immunization with a mixture of native HMW1A and HMW2A proteins resulted in partial protection in the

chinchilla intrabulla challenge model of otitis media (ref. 9). The production yields of native HMW proteins from *H. influenzae* strains are very low, but a method for producing protective recombinant HMW (rHMW) proteins has been described in copending United States Patent Application No. 09/167,568 filed October 7, 1998 (WO 00/20609), assigned to the assignee hereof and the disclosure of which is incorporated herein by reference. The HMWB and HMWC proteins are thought to function as molecular chaperones, responsible for the correct processing and secretion of the HMWA proteins (ref. 10).

A second family of high molecular weight adhesion proteins has been identified in about 25% of NTHI and in encapsulated *H. influenzae* strains (refs. 11, 12, 13). The NTHi member of this second family is termed *Haemophilus influenzae* adhesin or Hia, and the homologous protein found in encapsulated strains is termed *Haemophilus influenzae* surface fibril protein or Hsf. The *hia* gene was originally cloned from an expression library using convalescent sera from an otitis media patient, which indicates that it is an important immunogen during disease. Production of the full-length recombinant Hia protein in *E. coli* appears to be toxic to the host, so a series of N-terminally truncated proteins was made as described in copending United States Patent Application No. 09/268,347 filed March 16, 1999 and in PCT Patent Application No. PCT/CA00/00289 filed March 16, 2000, both assigned to the assignee hereof and the disclosures of which are incorporated herein by reference. The V38 rHia protein was chosen for further development as a vaccine, but it was found that the first 6 amino acids of this protein were deleted from a portion of the product during synthesis in *E. coli*, leading to a mixture of V38 rHia and S44 rHia. When an expression construct was developed to produce the S44 rHia, it was found that the N-terminus was stable, with only S44 rHia product being made. The rHia products appear as a doublet on SDS-PAGE when expressed alone. However, when co-expressed with H91A Hin47, the S44 rHia is produced as a single band, as described below.

The *S. pneumoniae* antigen, pneumococcal surface adhesin A or PsaA, is a protective antigen in an animal model (ref. 14), which is produced in high yield from *E. coli* as a 37 kDa protein. The protein may be produced as a lipoprotein if the *psaA* gene contains a sequence encoding a lipoprotein leader sequence, or as a soluble

protein if the gene encodes the mature protein. The protein and the encoding nucleotide sequence are described in US Patent No. 5,854,466, the disclosure of which is incorporated herein by reference. When co-expressed with H91A Hin47, both proteins are produced in high yield, as described below. They may be separated by
 5 hydroxylapatite (HTP) column chromatography during purification, resulting in the high level production of two vaccine components from different organisms, as described herein.

The over-production of *E. coli* chaperone proteins DnaK, DnaJ and GrpG (Hsp70) or GroEL and GroES (Hsp60) results in increased solubility of recombinant
 10 human protein kinases Csk, Fyn or Lck (ref. 15). These chaperones have also been shown to aid in the refolding of an allergen (Japanese cedar pollen) in *E. coli* (ref. 16). The *E. coli* Skp chaperone has also been used to increase the solubility of recombinant single-chain antibody fragments when co-expressed in *E. coli* (ref. 17). All these systems use a native *E. coli* chaperone to aid in the solubility and folding of
 15 recombinant proteins in *E. coli*. The present invention, for the first time, uses a heterologous protein as the chaperone

SUMMARY OF THE INVENTION

The present invention is directed to the expression of recombinant protein and expression vectors for utilization therein. In one feature of the present invention, such
 20 expression is effected in conjunction with expression of non-proteolytic analogs of *Haemophilus* Hin47 and in another feature of the present invention, such expression is effected in conjunction with expression of a high molecular weight protein of non-typeable *Haemophilus* which is *hmwBC*, *hmwB* or *hmwC*.

Accordingly, in one aspect of the present invention, there is provided an
 25 expression vector, comprising a nucleic acid molecule encoding a non-proteolytic analog of a Hin47 protein of a strain of *Haemophilus* including a portion thereof encoding the leader sequence for said non-proteolytic analog, and a promoter operatively connected to said nucleic acid molecule to direct expression of said non-proteolytic analog of a Hin47 protein having said leader sequence in a host
 30 cell.

In the various aspects of the invention involving a non-proteolytic analog of Hin47 protein, such analog may be a mutation of natural Hin47 protein in

which at least one amino acid selected from the group consisting of amino acids 91, 121 and 195 to 201 of natural Hin47 protein has been deleted or replaced by another amino acid. Preferably, the analog has histidine 91 replaced by alanine. This specific analog is termed H91A Hin47.

5 The vector may be a plasmid vector which may be one having the identifying characteristics of plasmid JB-3120-2 as seen in Figure 1A, such identifying characteristics being the nucleic acid sequences and restriction sites identified therein.

 In accordance with another aspect of the present invention, there is provided an expression vector for expression of a recombinant protein in a host cell, comprising a
10 nucleic acid molecule encoding a non-proteolytic analog of a *Haemophilus* Hin47 protein, at least one additional nucleic acid molecule encoding a recombinant protein, and at least one regulatory element operatively connected to said first nucleic acid molecule and said at least one additional nucleic acid molecule to effect expression of at least said recombinant protein in the host cell.

15 In one embodiment, the nucleic acid molecule encoding the non-proteolytic analog of a Hin47 protein includes a portion thereof encoding the leader sequence of the non-proteolytic analog, or such portion may be absent.

 The at least one additional nucleic acid molecule may encode a Hia or Hsf protein of a strain of *Haemophilus influenzae*, specifically a Hia protein which is N-terminally truncated. The N-terminal truncation may be S44 or V38. The construction
20 of such N-terminal truncations is described below.

 The vector may be a plasmid vector, which may be one having the identifying characteristics of plasmid DS-2542-2-2 as seen in Figure 5 or of plasmid JB-3145-1 seen in Figure 10, for expression of N-terminally truncated Hia proteins. Such
25 identifying characteristics are the nucleic acid sequences and restriction sites seen in the respective Figures.

 The at least one additional nucleic acid molecule may encode a PsaA protein of a strain of *Streptococcus pneumoniae*. The vector may be a plasmid vector having the identifying characteristics of plasmid JB-3073R-1 as seen in Figure 12 or of
30 plasmid JB-3090-1 or JB-3090-7, as seen in Figure 13, and expressing the PsaA protein. Such identifying characteristics are the nucleic acid sequences and restriction sites seen in the respective Figures.

The expression vector provided in this aspect of the present invention may be utilized in the generation of a recombinant protein by expression from a suitable host cell, such as *E. coli*. Accordingly, in another aspect of the present invention, there is provided a method for expressing at least one protein, which comprises providing a
 5 first nucleic acid molecule encoding a non-proteolytic analog of a Hin47 protein of *Haemophilus*; isolating at least one additional nucleic acid molecule encoding a protein other than Hin47; introducing the first nucleic acid molecule and the at least one additional nucleic acid molecule into a cell to produce a transformed cell; and growing the transformed cell to produce at least one protein. The nucleic
 10 acid molecules and regulatory elements may be incorporated into any of the specific expression vectors discussed above.

As noted above, one feature of the present invention involves vectors based on nucleic acid encoding high molecular weight (HMW) protein of a non-typeable strain of *Haemophilus*. Accordingly, in accordance with a further aspect of the present
 15 invention, there is provided an expression vector, comprising a nucleic acid molecule encoding a high molecular weight protein of a non-typeable strain of *Haemophilus* selected from the group consisting of *hmwB* and *hmwC*, and a promoter operatively connected to said nucleic acid molecule to direct expression of said high molecular weight protein in a host cell.

20 The vector may be a plasmid vector which may have the identifying characteristics of IN-137-1-16 shown in Figure 18A or of pT7 *hmwC* shown in Figure 19A, such identifying characteristics being the nucleic acid sequences and restrictions sites identified in the respective Figures.

The vectors, along with corresponding vectors including the *hmwBC* gene,
 25 may be used to construct expression vectors for the recombinant expression of proteins in a host cell. Accordingly, a yet further aspect of the present invention provides an expression vector for expression of a recombinant protein in a host cell, comprising a nucleic acid molecule encoding a high molecular weight (HMW) protein of a non-typeable strain of *Haemophilus* selected from the group
 30 consisting of *hmwBC*, *hmwB* and *hmwC*, at least one additional nucleic acid molecule encoding the recombinant protein, and at least one regulatory element operatively connected to said first nucleic acid molecule and said at least one

additional nucleic acid molecule to effect expression of at least said recombinant protein in the host cell.

In the latter vector, the at least one additional nucleic acid molecule may be inserted into a plasmid having the identifying characteristics of IN-52-1-13 as shown in Figure 17A, or of IN-137-1-16 shown in Figure 18A, or pT7 *hmvC* shown in Figure 19A, under the control of the regulatory element(s). Such identifying characteristics are the nucleic acid molecules and restriction sites identified in the respective Figures.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be further understood from the following description with reference to the accompanying drawings, in which:

Figure 1A describes the construction of vector JB-3120-2, a plasmid containing the *H91A hin47* gene including the sequence encoding the leader sequence. Restriction sites are: B, *Bam*H I; Bg, *Bgl* II; Cl, *Cla* I; H, *Hind* III; Nde, *Nde* I; Ps, *Pst* I; Pv, *Pvu* I; R, *Eco*R I; S, *Sal* I; Xb, *Xba* I; Xho, *Xho* I. Other abbreviations are: T7p, T7 promoter; htrA, wild-type *Hin47* gene; ApR, ampicillin resistance; TetR, tetracycline resistance; 5'f, 5'-flanking sequence; 3'f, 3'-flanking sequence. The X marks the site of the H91A mutation.

Figure 1B describes the oligonucleotides used for PCR amplification of the sequence encoding the leader. Sense strand (6931.SL) SEQ ID No: 1, encoded amino acid sequence SEQ ID No: 2; anti-sense strand (6932.SL) SEQ ID No: 3, complementary strand SEQ ID No: 4, encoded amino acid sequence SEQ ID No: 5.

Figure 2 contains an SDS-PAGE analysis of the production of H91A *Hin47*, with or without its leader sequence. Lane 1, H91A *hin47* - leader, t₀; lane 2, H91A *hin47* - leader, t₄; lane 3, H91A *hin47* + leader, t₀; H91A *hin47* + leader, t₄.

Figure 3 shows the purification scheme for H91A *Hin47* with leader.

Figure 4, having Panels A and B, contains a gel analysis of the extraction of H91A *Hin47* with (Panel A) or without (Panel B) its leader sequence. Lane 1, pre-stained protein molecular weight markers; lane 2, *E. coli* whole cell lysates; lane 3, soluble proteins in 50 mM Tris-HCl, pH 8.0 extraction; lane 4, soluble proteins in 50 mM Tris-HCl, pH 8.0/ 0.5% Triton X-100 /10 mM EDTA extraction; lane 5, pellets after the two extractions.

Figure 5 shows the construction of vector DS-2342-2-2, a plasmid containing the *T7 H91A hin47* and *T7 V38 hia* gene cassettes. The *H91A hin47* gene encodes the mature protein. Restriction sites are: B, *Bam*H I; Bg, *Bgl* II; H, *Hind* III; Nde, *Nde* I; Ps, *Pst* I; R, *Eco*R I; S, *Sal* I. Other abbreviations are: CAP, calf alkaline phosphatase; T7p, T7 promoter; ApR, ampicillin resistance; KanR, kanamycin resistance; TetR, tetracycline resistance.

Figure 6 contains an SDS-PAGE analysis of the production of V38 rHia and H91A Hin47, when co-expressed from the same plasmid. Lane 1, V38 rHia + H91A Hin47, t₀; Lane 2, V38 rHia + H91A Hin47, t₄; V38 rHia, t₄.

Figure 7 shows the purification scheme for V38 rHia when co-expressed with H91A Hin47.

Figure 8 contains an SDS-PAGE analysis of the purification of V38 rHia after co-expression with H91A Hin47. Lane 1, Prestained molecular weight markers; lane 2, *E. coli* cell lysate; lane 3, soluble proteins after 50 mM Tris-HCl, pH 8.0 / 0.1 M NaCl extraction; lane 4, soluble proteins in 50 mM Tris-HCl, pH 8.0/ 0.5% Triton X-100/ 10 mM EDTA extraction; lane 5, soluble proteins in 50 mM Tris-HCl, pH 8.0/ 1% octylglucoside extraction; lane 6, flow-through fraction after DEAE-Sephacel column; lane 7, flow-through fraction after HTP column; lane 8, purified H91A Hin47; lane 9, purified rHia protein.

Figure 9 shows the construction of vector JB-3134-1-1, a plasmid containing the *T7 H91A hin47* and *T7 S44 hia* gene cassettes. The *H91A hin47* gene encodes the mature protein. Restriction sites are: B, *Bam*H I; Bg, *Bgl* II; Cl, *Cla* I; H, *Hind* III; Nde, *Nde* I; Ps, *Pst* I; R, *Eco*R I. Other abbreviations are: CAP, calf alkaline phosphatase; T7p, T7 promoter; ApR, ampicillin resistance; KanR, kanamycin resistance.

Figure 10 shows the construction of vector JB-3145-1, a plasmid containing the *T7 H91A hin47* and *T7 S44 hia* gene cassettes. The *H91A hin47* gene encodes the protein with its leader sequence. Restriction sites are: B, *Bam*H I; Bg, *Bgl* II; Cl, *Cla* I; H, *Hind* III; Nde, *Nde* I; Ps, *Pst* I; R, *Eco*R I. Other abbreviations are: CAP, calf alkaline phosphatase; T7p, T7 promoter; ApR, ampicillin resistance; KanR, kanamycin resistance.

Figure 11 contains an SDS-PAGE analysis of the production of S44 rHia and H91A Hin47 \pm leader, when co-expressed from the same plasmid. Lane 1, H91A Hin47 - leader, t_0 ; lane 2, H91A Hin47 - leader, t_4 ; lane 3, H91A Hin47 + leader, t_4 ; lane 4, S44 rHia, t_4 ; lane 5, H91A Hin47 (-L) + S44 rHia, t_4 ; lane 6, H91A Hin47 (+L) + S44 rHia, t_4 .

Figure 12A shows the construction of vector JB-3073R-1, a plasmid containing the *T7 psaA* and *T7 H91A hin47* gene cassettes. The *psaA* gene encodes its endogenous leader sequence. Restriction sites are: B, *BamH* I; Bg, *Bgl* II; Cl, *Cla* I; H, *Hind* III; Nde, *Nde* I; Ps, *Pst* I; R, *EcoR* I, Xb, *Xba* I. Other abbreviations are: CAP, calf alkaline phosphatase; T7p, T7 promoter; ApR, ampicillin resistance; KanR*, kanamycin resistance gene with internal *Hind* III and *Xho* I sites deleted.

Figure 12B shows the oligonucleotide primers used to amplify *psaA* (+ leader). Sense strand (6850.SL), SEQ ID No: 26, encoded amino acid sequence, SEQ ID No: 27; anti-sense strand (6852.SL) SEQ ID No: 28, complementary strand, SEQ ID No: 29.

Figure 13A shows the construction of vectors JB-3090-1 and JB-3090-7, plasmids containing the *T7 psaA* and *T7 H91A hin47* gene cassettes, in different orientations. The *psaA* gene encodes the mature protein. Restriction sites are: B, *BamH* I; Bg, *Bgl* II; Cl, *Cla* I; H, *Hind* III; Nde, *Nde* I; Ps, *Pst* I; R, *EcoR* I, Xb, *Xba* I. Other abbreviations are: CAP, calf alkaline phosphatase; T7p, T7 promoter; ApR, ampicillin resistance; KanR*, kanamycin resistance gene with internal *Hind* III and *Xho* I sites deleted.

Figure 13B shows the oligonucleotide primers used to amplify *psaA* (- leader). Sense strand (6851.SL), SEQ ID No: 30, encoded amino acid sequence, SEQ ID No: 31; anti-sense strand (6852.SL) SEQ ID No: 28, complementary strand, SEQ ID No: 29.

Figure 14 contains an SDS-PAGE analysis of the production of rPsaA \pm leader and H91A Hin47 proteins, when co-expressed from the same plasmid. Lane 1, H91A Hin47 + rPsaA (+L) at t_0 ; lane 2, H91A Hin47 + rPsaA (+L) at t_4 (< > orientation); lane 3, H91A Hin47 + rPsaA (+L) at t_4 (> > orientation); lane 4, H91A Hin47 + rPsaA (-L) at t_4 (> > orientation).

Figure 15 shows the purification scheme for H91A Hin47 and rPsaA (without leader), when co-produced.

Figure 16, having Panels A and B, contains SDS-PAGE analysis of the purification of H91A Hin47 (Panel A) and rPsaA (Panel B) (without leader). Lane 1, 5
Prestained molecular weight markers; lane 2, *E. coli* cell lysate; lane 3, soluble proteins after 50 mM Tris-HCl, pH 8.0 extraction; lane 4, purification on DEAE-Sephacel column; lane 5, purification on HTP column; lane 6, flow-through fraction after Sartobind Q membrane, purified H91A Hin47 protein or rPsaA.

Figure 17A describes the construction of IN-52-1-13 that co-expresses the *H.*
10 *influenzae* *hmwB* and *hmwC* genes. Restriction sites are: B, *BamH* I; Bg, *Bgl* II; H, *Hind* III; Nde, *Nde* I; Ps, *Pst* I; R, *EcoR* I; S, *Sal* I; Xba, *Xba* I; Xho, *Xho* I. Other abbreviations are: T7p, T7 promoter; ApR, ampicillin resistance; KanR, kanamycin resistance.

Figure 17B illustrates the oligonucleotide primers used to PCR amplify the
15 *Nde* I-*EcoR* I 5' *hmwB* fragment. Sense strand (7072.SL) SEQ ID No: 6, encoded amino acid sequence SEQ ID No: 7; anti-sense strand (5950.SL) SEQ ID No: 8, complementary strand SEQ ID No: 9, encoded amino acid sequence SEQ ID No: 10.

Figure 18A shows the construction of IN-137-1-16 to express the *H.*
20 *influenzae* *hmwB* gene alone. Restriction sites are: B, *BamH* I; Bg, *Bgl* II; Cl, *Cla* I; H, *Hind* III; Nde, *Nde* I; Ps, *Pst* I; R, *EcoR* I, Xho, *Xho* I. Other abbreviations are: CAP, calf alkaline phosphatase; T7p, T7 promoter; ApR, ampicillin resistance.

Figure 18B illustrates the oligonucleotides used for construction of the *Hind*
III-*BamH* I 3' *hmwB* fragment. 7073.SL, SEQ ID No: 11; 7074.SL, SEQ ID No: 12; encoded amino acid sequence, SEQ ID No: 13; 7075.SL, SEQ ID No: 14, 7076.SL,
25 SEQ ID No: 15.

Figure 19A shows the construction of a plasmid to express the *H. influenzae* *hmwC* gene. Restriction sites are: B, *BamH* I; Bg, *Bgl* II; Cl, *Cla* I; H, *Hind* III; Nde, *Nde* I; Ps, *Pst* I; R, *EcoR* I; Xho, *Xho* I. Other abbreviations are: CAP, calf alkaline phosphatase; T7p, T7 promoter; ApR, ampicillin resistance.

30 Figure 19B illustrates the oligonucleotide primers used to PCR amplify the *Nde* I-*Xho* I 5' *hmwC* fragment. Sense strand (7077.SL) SEQ ID No: 16, encoded

amino acid sequence, SEQ ID No: 17; anti-sense strand (7078.SL) SEQ ID No: 18, complementary strand SEQ ID No: 19, encoded amino acid sequence SEQ ID No: 20.

Figure 19C illustrates the oligonucleotides used to construct the *Hind* III-*Bam*HI 3' *hmrC* fragment. 7079.SL, SEQ ID No.: 21; 7080.SL, SEQ ID No: 22;
 5 encoded amino acid sequence, SEQ ID No: 23; 7081.SL, SEQ ID No: 24; 7082.SL, SEQ ID No: 25.

GENERAL DESCRIPTION OF THE INVENTION

For clarity of disclosure, and not by way of limitation, the detailed description of the invention is divided into the following sections:

10 1. **Production of recombinant *H. influenzae* H91A Hin47 protein with its leader sequence.**

The native bacterial HtrA protein (*H. influenzae* Hin47) is a stress response protein located in the periplasmic membrane and responsible for survival of the organism under stress conditions, such as high temperature. It is a serine protease that
 15 degrades improperly folded de novo synthesized proteins. In the aforementioned US Patent No. 5,506,139, there is described the production of high yield (40 to 50% of total *E. coli* proteins), soluble, mature wild-type recombinant *H. influenzae* Hin47 protein from *E. coli*. The rHtrA (rHin47) protein had serine protease activity, which rendered it unstable after purification. Several analogues of Hin47 were generated by
 20 site-directed mutagenesis and the H91A Hin47 recombinant protein was found to be stable, of high yield, and protective in animal models. It had lost all measurable serine protease activity. When produced as the soluble mature protein, H91A Hin47 seemed to increase the solubility of co-produced proteins, a property which can be advantageous, as described below.

25 Stress response proteins may function as chaperones, serving to stabilize other expressed proteins. The H91A Hin47 protein has been produced with its endogenous leader sequence in an attempt to localize it to the periplasmic membrane and mimic the HtrA chaperone function. Since the endogenous serine protease activity has been ablated, it was hoped that H91A Hin47 might stabilize co-produced proteins in *E. coli*.
 30 The H91A Hin47 (+ leader) protein was made at 20 to 25% of total *E. coli* protein (Figure 2) and was found to be insoluble after extraction with Triton X-100,

suggesting that it was expressed either as a membrane-bound protein or inclusion bodies (Figure 4).

2. Production of recombinant *H. influenzae* Hia protein in the presence of H91A Hin47, with or without a leader sequence.

5 The *H. influenzae* Hia or Hsf proteins are demonstrated adhesins and as such are important vaccine candidates. The production of recombinant *H. influenzae* Hia proteins from *E. coli* has been described in the aforementioned US Patent Application No. 09/268,347. The full-length proteins were expressed at very low levels and were apparently toxic to *E. coli*. A series of truncated rHia proteins was made, which were
10 sequentially deleted at the N-terminus. The V38 rHia protein was produced as “soft” inclusion bodies and was purified, as described in the aforementioned US Patent Application No. 09/268,347. When the V38 rHia protein was co-produced with mature H91A Hin47, its solubility was increased. This led to an improved recovery during protein purification, and represents a novel use of mature H91A Hin47 (Figure 8).
15 When analysed by SDS-PAGE, the V38 rHia protein was apparently produced as two doublets, whether or not it was co-produced with mature H91A Hin47 (Fig 6).

The S44 rHia protein, prepared as described in the aforementioned PCT Patent Application No. PCT/CA00/00289 filed March 16, 2000, was also produced as “soft” inclusion bodies and was purified by the same process as the V38 rHia protein. When
20 analysed by SDS-PAGE, the S44 rHia protein was apparently produced as two doublets, if produced alone. When S44 rHia was co-produced with mature H91A Hin47, SDS-PAGE analysis revealed that it was apparently a single species (Figure 11). This apparent stabilization of a co-produced protein represents a novel use of mature H91A Hin47.

25 3. Production of recombinant *S. pneumoniae* PsaA protein in the presence of *H. influenzae* H91A Hin47.

The majority of acute bacterial otitis media is caused by *S. pneumoniae*, *H. influenzae* and *M. catarrhalis* infections. A broadly effective vaccine against this disease would ideally include antigens from all three organisms. The production of a
30 multi-component vaccine based upon recombinant proteins can be time-consuming and/or costly. If antigens could be co-produced, the cycle time for vaccine preparation could be reduced. In order for this to be effective, the antigens should be made in

similar quantities, if they are to be combined in a 1:1 ratio in the final vaccine. It must also be possible to separate them during purification.

The *S. pneumoniae* PsaA protein is a demonstrated adhesin that is protective in an animal model, and, as such, represents an important vaccine candidate. The native
 5 PsaA protein is a lipoprotein. The recombinant mature PsaA and lipo PsaA proteins are both made in high yield (30 to 40% of total protein) from *E. coli*. The mature protein is produced as a soluble protein and the lipoprotein appears to be membrane-associated. The recombinant mature H91A Hin47 vaccine component is also produced in high yield at 40 to 50% of total *E. coli* proteins. When the rPsaA and
 10 H91A Hin47 proteins are co-produced, they are still made in high yield, at 20 to 30% of total protein each (Figure 14).

The procedure for purification of the mature rPsaA and H91A Hin47 proteins is shown in Figure 16. Both H91A Hin47 and rPsaA (without leader) were expressed as soluble proteins. Separation of H91A Hin47 from rPsaA was achieved on a DEAE-
 15 Sephacel column, to which rPsaA bound, whereas H91A Hin47 did not. Further purification of both proteins included HTP chromatography and Sartobind Q-membrane.

4. Production of recombinant *H. influenzae* HMWB and/or HMWC proteins as potential chaperones.

20 The *H. influenzae* HMWA protein is a demonstrated adhesin that is protective in animal models. The production of rHMWA proteins has been described in the aforementioned US Patent Application No. 09/167,568. The *H. influenzae* HMWA protein is produced as a large precursor, from which a 35 kDa N-terminal fragment is cleaved during processing and secretion. The *H. influenzae* HMWA protein is
 25 encoded as part of an operon, *hmwABC*, that also encodes two accessory proteins termed HMWB and HMWC, that are thought to function as chaperones. The rHMWB and rHMWC proteins are made in good yield from *E. coli*, when expressed from the *hmwABC* operon. It has been demonstrated that the properties of a recombinant protein can be significantly altered when co-produced with the putative
 30 chaperone H91A Hin47. It would be interesting to determine what effect there would be on recombinant proteins co-produced with the *H. influenzae* rHMWB and/or rHMWC putative chaperone proteins.

It would be advantageous to express the *hmwB* and *hmwC* genes separately. Therefore, vectors have been designed to express the individual *hmwB*, *hmwC*, or *hmwBC* genes. Other genes encoding proteins of interest may be co-expressed with the *hmwB*, *hmwC*, or *hmwBC* genes.

5

EXAMPLES

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific Examples. These Examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Changes in form and substitution of
10 equivalents are contemplated as circumstances may suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitations.

Methods of molecular genetics, protein biochemistry, immunology and fermentation technology used, but not explicitly described in this disclosure and these
15 Examples, are amply reported in the scientific literature and are well within the ability of those skilled in the art.

Example 1

This Example describes the construction of plasmid JB-3120-2, which contains the *T7 H91A hin47* gene encoding the endogenous leader sequence. The
20 procedure employed is shown schematically in Figure 1A.

The production of the mature recombinant H91A Hin47 protein from *E. coli* has been described in the aforementioned U.S. Patent No. 5,506,139. This protein was produced at 40 to 50% of total protein in a soluble form. The bacterial HtrA proteins are located in the periplasmic membrane and may function as chaperones if located
25 there. In order to direct the mutant, non-proteolytic H91A Hin47 protein to the periplasmic membrane, the endogenous leader was added. Plasmid DS-2140-3 is a pBR328-based plasmid that contains the *T7 H91A hin47* gene cassette between *EcoR* I and *Cla* I sites (Figure 1A). Plasmid JB-1172-2-5 is a pUC-based plasmid that contains the wild-type *htrA* gene with 5'- and 3'-flanking sequences. Plasmid JB-
30 1172-2-5 was digested with *Cla* I and *Sal* I and the 0.6 kb 3'-flanking fragment was purified. Plasmid DS-2140-3 was digested with *Cla* I and *Sal* I, the 5.1 kb fragment purified, and the 3'-flanking fragment inserted, to generate plasmid JB-2706-9.

Plasmid DS-1843-2 is a pBR328-based vector into which a multiple cloning site has been inserted. JB-2706-9 was digested with *EcoR* I and *Sal* I, releasing the 2.5 kb *T7 H91A hin47/3'* gene sequence. The *EcoR* I-*Sal* I fragment was inserted into DS-1843-2, that had been digested with *EcoR* I and *Xho* I, generating plasmid JB-2721-1.

5 Plasmid JB-1172-2-5 was digested with *EcoR* I and *Pvu* I to release the 0.6 kb 5'-flanking sequence. Plasmid JB-2721-1 was digested with *EcoR* I and *Pvu* I to delete the T7 promoter sequence and the 5'-flanking sequence was inserted, generating plasmid JB-2750-8, that contains a genomic 5'-flanking/*htrA**/3'-flanking sequence with the H91A mutation. The HtrA leader sequence was PCR amplified from JB-

10 2750-8 on a 0.25 kb *Nde* I-*Pvu* I fragment, using the oligonucleotide primers shown in Figure 1B. Plasmid JB-2750-8 was digested with *Pvu* I and *Pst* I and the 1.7 kb H91A *hin47/3'*-flanking fragment was purified. Vector pT7-7 was digested with *Nde* I and *Pst* I and the *Nde* I-*Pvu* I and *Pvu* I-*Pst* I fragments inserted, to generate plasmid JB-3120-2. Plasmid DNA was introduced into electrocompetent *E. coli* BL21(DE3) cells

15 using a BioRad electroporator and recombinant *E. coli* strain JB-3129-1 was grown for protein analysis, as described in the following Example.

Example 2

This Example describes the production and purification of recombinant H91A Hin47 protein with its endogenous leader sequence.

20 Cells were grown at 37°C in NZCYM medium using the appropriate antibiotic selection to A₅₇₈ of 0.3 before addition of lactose to 1.0% for 4 hours. Samples were adjusted to 0.2 OD/μl with SDS-PAGE lysis + loading buffer and the same amount of each protein sample was loaded onto SDS-PAGE gels (ref. 18). The mature H91A Hin47 protein was produced at ~50% of total protein, while the H91A Hin47 + leader

25 protein was produced at 20 to 25% of total protein (Figure 2).

The purification of the mature soluble H91A Hin47 protein has been described in US Patent No. 5,506,139. The H91A Hin47 + leader protein was found to be associated with the pellet after two extractions of *E. coli* cells with 50 mM Tris-HCl, pH 8.0 and 50 mM Tris-HCl, pH 8.0 containing 0.5% Triton X-100 and 10 mM

30 EDTA. The pellet containing H91A Hin47 was solubilized in 50 mM Tris-HCl, pH 8.0, containing 8M urea. After the pellets were dissolved, 50 mM Tris-HCl, pH 8.0 was added to bring the final urea concentration to 2 M.

The above solution was then applied to a Macro-prep ceramic hydroxyapatite column (HTP, Bio-Rad Laboratories) equilibrated in 10 mM Na-PO₄ buffer, pH 8.0. H91A Hin47 protein bound to the HTP column. After washing the column with 10 column volumes of 175 mM Na-PO₄, pH 8.0, H91A Hin47 was eluted from the HTP
 5 with 0.3 M Na-PO₄, pH 8.0. The amount of H91A Hin47 in the elution fractions was determined by the bicinchoninic acid (BCA) protein assay using BSA as a standard. The purity of final preparation was assessed by SDS-PAGE analysis.

Example 3

This Example illustrates the construction of plasmid DS-2342-2-2, which
 10 contains the *T7 H91A hin47*, *T7 V38 hia*, and *E. coli cer* genes. The procedure employed is shown schematically in Figure 5.

Plasmid DS-1872-2-2 is a pBR328-based vector containing a 2.2 kb *EcoR* I *T7 H91A hin47* gene cassette (Figure 5). Plasmid BK-96-2-11 is a pBR328-based vector that contains a *T7 V38 hia* gene cassette, the *E. coli cer* gene, and a kanamycin
 15 resistance gene; and this plasmid has been described in the aforementioned US Patent Application No. 09/268,347. BK-96-2-11 was linearized by digestion with *EcoR* I, dephosphorylated, and the *EcoR* I *T7 H91A hin47* gene fragment inserted, to generate plasmid DS-2342-2-2, that co-expresses the *H91A hin47* and *V38 hia* genes. This plasmid thus contains tandem *T7 H91A hin47* and *T7 V38 hia* genes in the same
 20 orientation. Plasmid DNA was introduced into electrocompetent *E. coli* BL21(DE3) cells using a BioRad electroporator, and recombinant *E. coli* strain DS-2350-3-1 was grown for protein analysis, as described in the following Example.

Example 4

This Example describes the production and purification of recombinant V38
 25 rHia protein that was co-produced with H91A Hin47.

Protein samples were prepared and analysed as described in Example 2. The V38 rHia and mature H91A Hin47 proteins were both produced upon induction (Figure 6). The V38 rHia protein appeared as a pair of doublets on SDS-PAGE, whether or not it was produced in the presence of H91A Hin47.

30 The purification of V38 rHia, produced as inclusion bodies, has been described in US Patent Application No. 09/268,347. When co-produced with H91A Hin47, the V38 rHia protein was apparently more soluble; and the majority of rHia protein was

recovered in the initial 50 mM Tris-HCl, pH 8.0/ 0.1 M NaCl extraction. As shown in Figures 7 and 8, the separation of rHia from H91A Hin47 was achieved through a HTP column, to which H91A Hin47 protein bound but rHia did not. After concentration of rHia by PEG 4000 or ammonium sulfate, the protein was further purified on a Superdex 200 gel filtration column, the same process used for the purification of rHia expressed as inclusion bodies. A Sartibond Q membrane was used as a final polishing step to further remove LPS and residual contaminants. The purity of rHia or H91A Hin47 was assessed by SDS-PAGE analysis (Figure 8), according to the procedure of Laemmli (ref. 18).

10 Example 5

This Example illustrates the construction of plasmid JB-3134-1-1, which contains the *T7 S44 hia* and *T7 H91A hin47* (no leader) genes. The procedure employed is shown schematically in Figure 9.

Plasmid DS-1298-1 is a pBR322-based plasmid (pEV, ref. 19) that contains the *T7 H91A hin47* gene on a 2.2 kb *Bgl* II-*Bam*H I fragment (Figure 9). Plasmid JB-2930-3 is a pBR328-based vector that contains the *T7 S44 hia*, *E. coli cer*, and kanamycin resistance genes and is described in the aforementioned PCT Patent Application No. PCT/CA00/00289. Plasmid JB-2930-3 was linearized by digestion with *Bgl* II, dephosphorylated, and the *Bgl* II-*Bam*H I *T7 H91A hin47* gene fragment inserted to generate plasmid JB-3134-1-1. This plasmid thus contains tandem *T7 H91A hin47* (-L) and *T7 S44 hia* genes in the same orientation. Plasmid DNA was introduced into electrocompetent *E. coli* BL21(DE3) cells using a BioRad electroporator, and recombinant *E. coli* strain JB-3144-1 was grown for protein analysis.

25 Example 6

This Example illustrates the construction of plasmid JB-3145-1, which contains the *T7 S44 hia* and *T7 H91A hin47* (with leader) genes. The procedure employed is shown schematically in Figure 10.

Plasmid JB-3120-2, prepared as described in Example 1, contains the *T7 H91A hin47* (+ leader) cassette on a *Bgl* II-*Cla* I fragment (Figure 10). Plasmid pEVvrf2 is a pBR322-based plasmid containing the γP_L promoter and a multiple cloning site (ref. 19). Plasmid pEVvrf2 was digested with *Bgl* II and *Cla* I, and the *T7 H91A hin47*

(+L) gene cassette was inserted to generate plasmid JB-3133-1-1. This plasmid contains the *T7 H91A hin47* (+L) gene cassette on a *Bgl* II-*Bam*H I fragment. Plasmid JB-2930-3 is a pBR328-based vector that contains the *T7 S44 hia*, *E. coli cer*, and kanamycin resistance genes, and is prepared as described in the aforementioned PCT Patent Application No. PCT/CA00/00289. Plasmid JB-2930-3 was digested with *Bgl* II, dephosphorylated, and the *Bgl* II-*Bam*H I *T7 H91A hin47* (+L) fragment was inserted to generate plasmid JB-3145-1. This plasmid thus contains tandem *T7 H91A hin47* (+L) and *T7 S44 hia* genes in the same orientation. Plasmid DNA was introduced into electrocompetent *E. coli* BL21(DE3) cells using a BioRad electroporator and recombinant *E. coli* strain JB-3153-1-1 was grown for protein analysis.

Example 7

This Example describes the production of recombinant S44 rHia protein that was co-produced with H91A Hin47 \pm leader.

Protein samples, produced by the plasmids JB-3134-1-1 and JB-3145-1, described in Examples 5 and 6, were prepared and analysed as described in Example 2. The S44 rHia and mature H91A Hin47 proteins were both produced upon induction (Figure 11). The S44 rHia protein appeared as a pair of doublets when expressed alone, but as a single band when co-expressed with H91A Hin47 (-L). The H91A Hin47 protein appears to have enhanced the stability of the co-produced S44 rHia protein. The S44 rHia and H91A Hin47 (with leader) proteins were both produced upon induction, although the amount of S44 rHia was significantly reduced (Figure 11).

Example 8

This Example describes the construction of plasmid JB-3073R-1, which contains the *T7 H91A hin47* and *T7 psaA* (with leader) genes. The procedure employed is shown schematically in Figure 12A.

The *H. influenzae* H91A Hin47 and *S. pneumoniae* rPsaA proteins are both potential vaccine candidates and are made in high yield from *E. coli* when expressed individually. The production time for these vaccine antigens can be significantly reduced if they could be co-expressed and separated by purification. Plasmid JB-2996-1-6 is an ampicillin resistant pET-based vector containing a *T7 psaA* (+ leader)

gene cassette encoding the 37 kDa lipo rPsaA protein (Figure 12A). PCR primers for amplification of the *psaA* (+ leader) gene are described in Figure 12B. Plasmid JB-3004-26 was derived from plasmid pUC-4K (Pharmacia) by site-directed mutagenesis of the kanamycin resistance (*kanR*) gene. The interior *Hind* III and *Xho* I sites were
 5 deleted, but the *Cla* I and *Sma* I sites were unchanged. Plasmid JB-2996-1-6 was linearized with *Pst* I, dephosphorylated, and the mutated *kanR* gene from JB-3004-26 was inserted to generate JB-3060-1-25. Plasmid DS-1298-1 is a pBR322-based plasmid containing the *T7 H91A hin47* gene, encoding the mature H91A Hin47 protein, on a 2.2 kb *Bgl* II-*Bam*H I fragment. Plasmid JB-3060-1-25 was linearized
 10 with *Bgl* II, dephosphorylated, and the *Bgl* II-*Bam*H I *T7 H91A hin47* gene inserted to generate JB-3073R-1. This plasmid thus contains tandem *T7 H91A hin47* and *T7 psaA* (+L) genes in the same orientation. Plasmid DNA was introduced into electrocompetent *E. coli* BL21(DE3) cells using a BioRad electroporator, and recombinant *E. coli* strain IA-181-1 was grown for protein analysis.

15 Example 9

This Example describes the construction of plasmids JB-3090-1 and JB-3090-7, which contain the *T7 H91A hin47* and *T7 psaA* (no leader) genes. The procedure employed is shown schematically in Figure 13A.

Plasmid JB-2996-2-2 is an ampicillin resistant pET-based vector containing a
 20 *T7 psaA* (- leader) gene cassette, encoding the mature rPsaA protein (Figure 13A). PCR primers to amplify *psaA* (- leader) gene are described in Figure 13B. Plasmid JB-3004-26 contains the mutated kanamycin resistance gene, as described in Example 8. Plasmid JB-2996-2-2 was linearized with *Pst* I, dephosphorylated, and the mutated *kanR* gene from JB-3004-26 was inserted to generate JB-3060-2-5. Plasmid DS-1298-
 25 1 is a pBR322-based plasmid containing the *T7 H91A hin47* gene encoding the mature H91A Hin47 protein on a 2.2 kb *Bgl* II-*Bam*H I fragment. Plasmid JB-3060-2-5 was linearized with *Bgl* II, dephosphorylated, and the *Bgl* II-*Bam*H I *T7 H91A hin47* gene inserted to generate plasmids JB-3090-1 and JB-3090-7. These plasmids differ only in the relative orientation of the inserted *T7 H91A hin47* gene. Plasmid JB-3090-7 thus
 30 contains tandem *T7 H91A hin47* and *T7 psaA* (-L) genes in the same orientation, while plasmid JB-3090-1 contains tandem *T7 H91A hin47* and *T7 psaA* (-L) genes in opposite orientations. It has been noted that the latter arrangement of genes is very

rarely cloned. Plasmid DNA was introduced into electrocompetent *E. coli* BL21(DE3) cells using a BioRad electroporator; and recombinant *E. coli* strains JB-3106-1-1 (from JB-3090-1) and JB-3106-2-1 (from JB-3090-7) were grown for protein analysis.

Example 10

5 This Example describes the production and purification of recombinant H91A Hin47 and PsaA \pm leader when co-produced from the same plasmid.

Protein samples, produced by plasmids JB-3073R-1, plasmid JB-3090-1 and plasmid JB-3090-7, described in Examples 8 and 9, were prepared and analysed as described in Example 2. The rPsaA protein was produced in good yield from all
10 strains, with or without its leader sequence (Figure 14). However, the H91A Hin47 protein was produced from only two of three strains. When the tandem genes were arranged in the same orientation, both rPsaA and H91A Hin47 were produced in high yield. Strain JB-3106-1-1, generated from plasmid JB-3090-1 that contains the tandem genes in opposite orientations, did not produce any H91A Hin47.

15 The scheme for separation and purification of the H91A Hin47 and rPsaA proteins is shown in Figure 15. Both H91A Hin47 and rPsaA (without leader) were expressed as soluble proteins. After extraction with 50 mM Tris-HCl, pH 8.0, the soluble sonicate fraction was applied to a DEAE-Sephacel column equilibrated in 50 mM Tris-HCl, pH 8.0. The majority of H91A Hin47 did not bind to the column and
20 was recovered in the flow-through fraction. In contrast, the majority of rPsaA bound to the DEAE-Sephacel. After washing with 10 column volumes of 50 mM Tris-HCl, pH 8.0/10 mM NaCl to remove contaminants, rPsaA was eluted in 50 mM Tris-HCl, pH 8.0 containing 30 mM NaCl. The H91A Hin47 or rPsaA fraction was further purified separately onto a Macro-prep ceramic hydroxylapatite column (HTP)
25 equilibrated in 10 mM Na-PO₄ buffer, pH 8.0. Both proteins bound to the HTP column. For the purification of H91A Hin47, the HTP column was washed with 10 column volumes of 175 mM Na-PO₄, pH 8.0, and H91A Hin47 was eluted with 0.3 M Na-PO₄, pH 8.0. For the purification of rPsaA, the HTP column was washed with 10 column volumes of 50 mM Na-PO₄, pH 8.0, and rPsaA was eluted with 0.2 M Na-
30 PO₄, pH 8.0. The purity of H91A Hin47 or rPsaA was assessed by SDS-PAGE analysis (Figure 16).

Example 11

This Example describes the construction of plasmid IN-52-1-13 that co-expresses *H. influenzae* *hmwB* and *hmwC* genes. The procedure employed is shown schematically in Figure 17A.

5 Plasmid JB-2641-1 is a pT7-based plasmid that contains the *hmwABC* genes with an *Xba* I site inserted at the 3'-end of *hmwA* (Figure 17A) and has been described in the aforementioned US Patent Application No. 09/167,568. Digestion with *Nde* I and *EcoR* I deletes a 610 bp fragment containing the *hmwA* gene and the 5'-end of the *hmwB* gene. The 5'-end of *hmwB* is created by PCR amplification that also introduces
 10 an *Nde* I site encoding a start Met, using the oligonucleotide primers shown in Figure 17B. The 460 bp *Nde* I-*EcoR* I PCR fragment is inserted into the *Nde* I-*EcoR* I vector to generate pT7 *hmwBC/cer/kanR* (IN-47-1). In order to introduce additional restriction enzyme sites for future constructions, the *Nde* I-*Sal* I fragment containing the complete T7 *hmwBC* gene cassette is inserted into pT7-7 to generate pT7 *hmwBC*
 15 (IN-52-1-13).

Example 12

This Example describes the construction of plasmid IN-137-1-16 that expresses *H. influenzae* *hmwB* alone. The procedure employed is shown schematically in Figure 18A.

20 The construction of plasmid pT7 *hmwBC* (IN-52-1-13) is described in Example 11. Digestion of plasmid IN-52-1-13 with *Bgl* II and *Hind* III generates a fragment containing the T7 promoter and most of the *hmwB* gene (Fig 18A). The 3'-end of *hmwB* is synthesized as a ~123 bp *Hind* III-*BamH* I fragment, using the oligonucleotides shown in Figure 18B. The *Bgl* II-*Hind* III and *Hind* III-*BamH* I
 25 fragments are inserted into pT7-7 that has been digested with *Bgl* II and *BamH* I, then dephosphorylated. The resultant plasmid, pT7 *hmwB* (IN-137-1-16), contains the T7 promoter and the full-length *hmwB* gene only, as a *Bgl* II-*BamH* I cassette that can be used for co-expression studies.

Example 13

30 This Example describes the construction of a plasmid to express *H. influenzae* *hmwC* alone. The procedure employed is shown schematically in Figure 19A.

The construction of plasmid pT7 *hmwBC* (IN-52-1-13) was described in Example 11. This vector contains the complete *hmwB* and *hmwC* genes, as well as ~1.3 kb of 3'-flanking sequence. Digestion of IN-52-1-13 with *Nde* I and *Xho* I deletes the *hmwB* gene and the 5'-end of *hmwC* gene(Figure 19A). The 5'-end of *hmwC* is created by PCR amplification that also introduces an *Nde* I site encoding a start Met. The oligonucleotide primers employed are shown in Figure 19B. The 950 bp *Nde* I-*Xho* I 5' *hmwC* PCR fragment is inserted into the *Nde* I-*Xho* I vector to generate pT7 *hmwC/3'* (IN-109-1). In order to create a plasmid containing only the *hmwC* gene with no 3'-flanking sequence, IN-109-1 was digested with *Bgl* II and *Hind* III and the ~2.2 kb fragment containing the T7 promoter and most of the *hmwC* gene was purified. The 3'-end of the *hmwC* gene is synthesized as a 80 bp *Hind* III-*Bam*HI fragment from the oligonucleotides shown in Figure 19C. The *Bgl* II-*Hind* III and *Hind* III-*Bam*HI fragments are inserted into pT7-7 that has been digested with *Bgl* II and *Bam*HI and dephosphorylated. The resultant plasmid, pT7 *hmwC*, contains the T7 promoter and the full-length *hmwC* gene only as a *Bgl* II-*Bam*HI cassette that can be used for co-expression studies.

SUMMARY OF THE DISCLOSURE

In summary of this disclosure, there is provided a heterologous chaperone effect in the expression of recombinant proteins. Modifications are possible within the scope of the invention.

REFERENCES

1. Ellis, J. (1987) Proteins as molecular chaperones. *Nature* 328: 378-379.
2. Bluestone, C.D. (1982) Current concepts in otolaryngology. Otitis media in children: to treat or not to treat? *N. Engl. J. Med.* 306:1399-1404.
3. Loosmore, S.M., Yang, Y-P., Oomen, R., Shortreed, J.M., Coleman, D.C., and Klein, M.H. (1998) The *Haemophilus influenzae* HtrA protein is a protective antigen. *Infect. Immun.* 66:899-906.
4. Pallen, M.J. and Wren, B.W. (1997) The HtrA family of serine proteases. *Molec. Microbiol.* 26: 209-221.
5. Barenkamp, S.J. and Bodor, F.F. (1990) Development of serum bactericidal activity following nontypable *Haemophilus influenzae* acute otitis media. *Pediatr. Infect. Dis.* 9:333-339.
6. Barenkamp, S.J. and St. Geme III, J.W. (1994) Genes encoding high-molecular-weight adhesion proteins of nontypeable *Haemophilus influenzae* are part of gene clusters. *Infect. Immun.* 62:3320-3328.
7. St. Geme III, J.W., Kumar, V.V., Cutter, D., and Barenkamp, S.J. (1998) Prevalence and distribution of the *hmw* and *hia* genes and the HMW and Hia adhesins among genetically diverse strains of nontypeable *Haemophilus influenzae*. *Infect. Immun.* 66:364-368.
8. St. Geme III, J.W., Falkow, S. and Barenkamp, S.J. (1993) High-molecular-weight proteins of nontypeable *Haemophilus influenzae* mediate attachment to human epithelial cells. *Proc. Natl. Acad. Sci. USA* 90:2875-2879.
9. Barenkamp, S.J. (1996) Immunization with high-molecular-weight adhesion proteins of nontypeable *Haemophilus influenzae* modifies experimental otitis media in chinchillas. *Infect. Immun.* 64:1246-1251.
10. St. Geme III, J.W. and Grass, S. (1998) Secretion of the *Haemophilus influenzae* HMW1 and HMW2 adhesins involves a periplasmic intermediate and requires the HMWB and HMWC proteins. *Molec. Microbiol.* 27: 617-630.
11. St. Geme III, J.W. and Cutter, D. (1995) Evidence that surface fibrils expressed by *Haemophilus influenzae* type b promote attachment to human epithelial cells. *Molec. Microbiol.* 15: 77-85.
12. Barenkamp, S.J. and St. Geme III, J.W. (1996) Identification of a second family of high-molecular-weight adhesion proteins expressed by non-typable *Haemophilus influenzae*. *Molec. Microbiol.* 19: 1215-1223.

13. St. Geme III, J.W., Cutter, D., and Barenkamp, S.J. (1996) Characterization of the genetic locus encoding *Haemophilus influenzae* type b surface fibrils. *J. Bact.* 178: 6281-6287.
14. Talkington, D.F., Brown, B.G., Tharpe, J.A., Koenig, A., and Russell, H. (1996) Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). *Microb. Pathog.* 21: 17-22.
15. Caspers, P., Stieger, M., and Burn, P. (1994) Overproduction of bacterial chaperones improves the solubility of recombinant protein tyrosine kinases in *Escherichia coli*. *Cell Mol Biol (Noisy-le-grand)* 40(5):635-44.
16. Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H., and Yura, T. (1998) Chaperone coexpression plasmids: differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES in assisting folding of an allergen of Japanese cedar pollen, Cryj2, in *Escherichia coli*. *Appl. Environ Microbiol* 64(5):1694-9.
17. Hayhurst, A, and Harris, W.J. (1999) *Escherichia coli* skp chaperone coexpression improves solubility and phage display of single-chain antibody fragments. *Protein Expr Purif* 15(3):336-43.
18. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T₄. *Nature* 227:680-685.
19. Crowl, R. et al., (1985) Versatile expression vectors for high-level synthesis of cloned gene products in *Escherichia coli*, *Gene*, 38:31-38.

CLAIMS

What we claim is:

1. An expression vector, comprising:
 - a nucleic acid molecule encoding a non-proteolytic analog of a Hin47 protein of a strain of *Haemophilus* including a portion thereof encoding the leader sequence for said non- proteolytic analog, and
 - a promoter operatively connected to said nucleic acid molecule to direct expression of said non-proteolytic analog of a Hin47 protein having said leader sequence in a host cell.
2. The vector of claim 1 wherein said non-proteolytic analog of Hin47 protein is a mutation of natural Hin47 protein in which at least one amino acid selected from the group consisting of amino acids 91, 121 and 195 to 201 of natural Hin47 protein has been deleted or replaced by a different amino acid.
3. The vector of claim 2 wherein histidine 91 is replaced by alanine.
4. The vector of claim 1 which is plasmid vector having the identifying characteristics of plasmid JB-3120-2 as seen in Figure 1A.
5. An expression vector for expression of a recombinant protein in a host cell, comprising:
 - a nucleic acid molecule encoding a non-proteolytic analog of a *Haemophilus* Hin47 protein,
 - at least one additional nucleic acid molecule encoding the recombinant protein, and
 - at least one regulatory element operatively connected to said first nucleic acid molecule and said at least one additional nucleic acid molecule to effect expression of at least said recombinant protein in the host cell.
6. The vector of claim 5 wherein said nucleic acid molecule encoding the non-proteolytic analog of a Hin47 protein includes a portion encoding the leader sequence for said non-proteolytic analog.
7. The vector of claim 6 wherein said non-proteolytic analog of Hin47 protein is a mutation of natural Hin47 protein in which at least one amino acid selected from the group consisting of amino acids 91, 121 and 195 to 201 of natural Hin47 protein has been deleted or replaced by a different amino acid.

8. The vector of claim 7 wherein histidine 91 is replaced by alanine.
9. The vector of claim 5 wherein said at least one additional nucleic acid molecule encodes a Hia or Hsf protein of a strain of *Haemophilus influenzae*.
10. The vector of claim 9 wherein said at least one additional nucleic acid molecule encodes a Hia protein which is N-terminally truncated.
11. The vector of claim 10 wherein said N-terminal truncation is S44 or V38.
12. The vector of claim 11 which is a plasmid vector having the identifying characteristics of plasmid DS-2342-2-2 as seen in Figure 5.
13. The vector of claim 11 which is a plasmid vector having the identifying characteristics of plasmid JB-3145-1 seen in Figure 10.
14. The vector of claim 5 wherein said at least one additional nucleic acid molecule encodes a PsaA protein of a strain of *Streptococcus pneumoniae*.
15. The vector of claim 14 which is a plasmid vector having the identifying characteristics of plasmid JB-3073R-1 as seen in Figure 12.
16. The vector of claim 14 which is a plasmid vector having the identifying characteristics of plasmid JB-3090-1 or JB-3090-7 as seen in Figure 13.
17. A method for expressing at least one protein, which comprises:
 - providing a first nucleic acid molecule encoding a non-proteolytic analog of a Hin47 protein of *Haemophilus*;
 - isolating at least one additional nucleic acid molecule encoding a protein other than Hin47;
 - introducing the first nucleic acid molecule and the at least one additional nucleic acid molecule into a cell to produce a transformed cell; and
 - growing the transformed cell to produce at least one protein.
18. The method of claim 17 wherein said first nucleic acid molecule contains a portion encoding the leader sequence for said non-proteolytic analog.
19. The method of claim 18 wherein said non-proteolytic analog of Hin47 protein is a mutation of natural Hin47 protein in which at least one amino acid selected from the group consisting of amino acids 91, 121 and 195 to 201 of natural Hin47 protein has been deleted or replaced by a different amino acid.
20. The method of claim 19 wherein histidine 91 is replaced by alanine.

21. The method of claim 20 wherein said at least one additional nucleic acid molecule encodes a Hia or Hsf protein of a strain of *Haemophilus influenzae*.
22. The method of claim 21 wherein said at least one additional nucleic acid molecule encodes a Hia protein which is N-terminally truncated.
23. The method of claim 22 wherein said N-terminal truncation is S44 or V38.
24. The method of claim 21 wherein said vector is a plasmid vector having the identifying characteristics of plasmid JB-3145-1 as shown in Figure 10.
25. The method of claim 20 wherein said at least one additional nucleic acid molecule encodes a PsaA protein of a strain of *Streptococcus pneumoniae*.
26. The method of claim 17 wherein said first nucleic acid molecule encodes the nature form of the non-proteolytic analog.
27. The method of claim 26 wherein said non-proteolytic analog of Hin47 protein is a mutation of natural Hin47 protein in which at least one amino acid selected from the group consisting of amino acids 91, 121 and 195 to 201 of natural Hin47 protein has been deleted or replaced by a different amino acid.
28. The method of claim 27 wherein histidine 91 is replaced by alanine.
29. The method of claim 28 wherein said at least one additional nucleic acid molecule encodes a Hia or Hsf protein of a strain of *Haemophilus influenzae*.
30. The method of claim 29 wherein said at least one additional nucleic acid molecule encodes a Hia protein which is N-terminally truncated.
31. The method of claim 30 wherein said N-terminal truncation is S44 or V38.
32. The method of claim 31 wherein said vector is a plasmid vector having the identifying characteristics of plasmid DS-2342-2-2 as seen in Figure 5.
33. The method of claim 31 wherein said vector is a plasmid vector having the identifying characteristics of plasmid JB-3134-1-1 as seen in Figure 9.
34. The method of claim 28 wherein said at least one additional nucleic acid molecule encodes a PsaA protein of a strain of *Streptococcus pneumoniae*.
35. The method of claim 34 wherein said vector is a plasmid vector having the identifying characteristics of plasmid JB-3073R-1 as seen in Figure 12.
36. The method of claim 34 wherein said vector is a plasmid vector having the identifying characteristics of plasmid JB-3090-1 or JB-3090-7 as seen in Figure 13.

37. An expression vector, comprising:

a nucleic acid molecule encoding a high molecular weight protein of a non-typeable strain of *Haemophilus* selected from the group consisting of *hmwB* and *hmwC*, and

a promoter operatively connected to said nucleic acid molecule to direct expression of said high molecular weight protein in a host cell.

38. The vector of claim 37 which is a plasmid vector having the identifying characteristics of plasmid IN-137-1-16 shown in Figure 18A.

39. The vector of claim 37 which is a plasmid vector having the identifying characteristics of pT7 *hmwC* shown in Figure 19A.

40. An expression vector for expression of a recombinant protein in a host cell, comprising:

a nucleic acid molecule encoding a high molecular weight (HMW) protein of a non-typeable strain of *Haemophilus* selected from the group consisting of *hmwBC*, *hmwB* and *hmwC*,

at least one additional nucleic acid molecule encoding the recombinant protein, and

at least one regulatory element operatively connected to said first nucleic acid molecule and said at least one additional nucleic acid molecule to effect expression of at least said recombinant protein in the host cell.

41. The expression vector of claim 40 wherein said at least one additional nucleic acid molecule is inserted into a plasmid having the identifying characteristics of plasmid IN-52-1-13 as shown in Figure 17A and under control of said at least one regulatory element.

42. The expression vector of claim 40 wherein said at least one additional nucleic acid molecule is inserted into a plasmid having the identifying characteristics of plasmid IN-137-1-16 shown in Figure 18A and under control of said at least one regulatory element.

43. The expression vector of claim 40 wherein said at least one additional nucleic acid molecule is inserted into a plasmid having the identifying characteristics of plasmid pT7 *hmwC* shown in Figure 19A and under control of said at least one regulatory element.


ABSTRACT OF THE DISCLOSURE

- Expression vectors are described which permit the recombinant expression of proteins which essentially contain, in addition to nucleic acid encoding the recombinant protein, nucleic acid encoding a non-proteolytic analog of *Haemophilus*
- 5 Hin47 protein, with or without leader sequence, or nucleic acid encoding high molecular weight proteins of non-typeable *Haemophilus*, which are *hmwB*, *hmwC* or *hmwBC*.

Figure 1B. Oligonucleotide primers to PCR amplify the Nde I-Pvu I fragment encoding the leader sequence of HtrA.

		Nde I													
			M	K	K	T	R	F	V	L	N	S		SEQ ID No: 2	
5'	GGCCG	CATATG	AAAAAA	ACACG	TTT	TG	TACT	AA	ATAGT	3'	6931.SL		SEQ ID No: 1		
		Pvu I													
			F	K	F	F	F	G	D	R	F	A	E	Q	SEQ ID No: 5
	TTTAAATTCTTCTTTGG	CGATCG	TTT	TGCC	GAACAA									SEQ ID No: 4	
3'	AAATTTAAGAAGAAACCGCTAGCAAAACGGCTTGTT	5'	6932.SL											SEQ ID No: 3	

Figure 2. Production of H91A Hin47 +/- leader



- 1. H91A Hin47 (- leader) t_0
- 2. H91A Hin47 (- leader) t_4
- 3. H91A Hin47 (+ leader) t_0
- 4. H91A Hin47 (+ leader) t_4

Figure 3. Purification of H91A Hin47 (+ leader) from *E. coli*






Figure 4. Extraction of H91A Hin47 +/- leader, produced in *E. coli*




1. Pre-stained markers
2. *E. coli* whole cells
3. Soluble proteins in 50 mM Tris-HCl extraction
4. Soluble proteins in Tris/EDTA/Triton-100 extraction
5. Remaining pellets

Figure 5. Construction of DS-2342-2-2, a plasmid containing *T7 H91A hin47* and *T7 V38 hia*



Co-exprn fig 5
pDS-2342

Figure 6. Production of V38 rHia and H91A Hin47 when co-expressed



- 1. V38 rHia and H91A Hin47 t_0
- 2. V38 rHia and H91A Hin47 t_4
- 3. V38 rHia alone t_4

Co-expn fig 6
V38hin

Figure 7. Purification of H91A Hin47 and V38 rHia from *E. coli*





Figure 8. Purification of H91A Hin47 and V38 rHia from *E. Coli*



- | | |
|--|------------------------|
| 1. Prestained molecular weight markers | 6. DEAE flow-through |
| 2. <i>E. coli</i> whole cell lysate | 7. HTP flow-through |
| 3. Tris/NaCl extract | 8. Purified H91A Hin47 |
| 4. Tris/ Triton X-100 / EDTA extract | 9. Purified rHia |
| 5. Tris/ OG extract | |

Figure 9. Construction of JB-3134-1-1, a plasmid containing T7 *H91A hin47* (- leader) and T7 *S44 hia*




Figure 10. Construction of JB-3145-1, a plasmid containing T7 *H91A hin47* (+ leader) and T7 *S44 hia*.





Figure 11. Production of S44 rHia and H91A Hin47 (+/-L), when co-expressed.



- | | |
|-------------------------------|-------|
| 1. H91A Hin47 (-L) | t_0 |
| 2. H91A Hin47 (-L) | t_4 |
| 3. H91A Hin47 (+L) | t_4 |
| 4. S44 rHia | t_4 |
| 5. H91A Hin47 (-L) + S44 rHia | t_4 |
| 6. H91A Hin47 (+L) + S44 rHia | t_4 |

Figure 12A. Construction of JB-3073R-1, a plasmid containing T7 *psaA* (+ leader) and T7 *H91A hin47*




Figure 12B. Oligonucleotide primers to PCR amplify psaA (+ native leader)

Sense:

Nde I
 M K K L G T L L V L
 5' CGGGATCC CATATG AAAAAATTAGGTACATTACTCGTTCTC 3' 6850.SL
 Srd ID no: 27
 Srd ID no: 26

Antisense:

CATGTGAGCTGGCGTTTTTTTAAGCTTGGCC
 3' GTACACTCGACCGCAAAAAA TTCGAA CCGG 5' 6852.SL
 Hind III
 Srd ID no: 29
 Srd ID no: 28

1000
 900
 800
 700
 600
 500
 400
 300
 200
 100
 0

Figure 13A. Construction of JB-3090-1 and JB-3090-7, plasmids containing T7 *psaA* (- leader) and T7 *H91A hin47*




Fig 13B. Oligonucleotide primers to PCR amplify psaA (- leader)


Sense:

5' CGGGATCC CATATG ^{M C A S G K K D T} TGTGCTAGCGGAAAAAAGATACA 3' 6851.SL JCR 10-20:31
JCR 10-20:30

Antisense:

CATGTGAGCTGGCGTTTTTTAAGCTTGGCC
3' GTACACTCGACCGCAAAAAA TTCGAA CCGG 5' 6852.SL JCR 10-20:29
Hind III JCR 10-20:28

Figure 14. Production of rPsaA +/- leader and H91A Hin47, when co-expressed



1. H91A Hin47 and rPsaA (+ leader), < > orientation t_0
2. H91A Hin47 and rPsaA (+ leader), < > orientation t_4
3. H91A Hin47 and rPsaA (+ leader), > > orientation t_4
4. H91A Hin47 and rPsaA (- leader), > > orientation t_4

Co-expn fig 14
psaahin

Figure 15. Purification of H91A Hin47 and rPsaA from *E. coli*






Figure 16. Purification of H91A Hin47 and rPsaA from *E. coli*



1. Pre-stained molecular weight markers
2. *E. coli* whole cell lysate
3. Soluble proteins in 50 mM Tris-HCl, pH 8.0 extraction
4. DEAE-Sepharose column
5. HTP column
6. Sartobind Q membrane

Figure 17A. Construction of a plasmid containing *T7 hmwBC*.



Co-exprn fig 17A
phmwBC

Figure 17B. Oligonucleotide primers for PCR amplification of Nde I-EcoR I 5' *hmvB* fragment.


coding strand:

		Nde I										
		M	K	N	I	K	S	R	L	K	L	
5'		GGCCG	CATATG	AAAAATATAAAAAGCAGATTAAACTC	3'	7072.SL		SEQ ID No: 7				
												SEQ ID No: 6

non-coding strand:

						EcoR I									
		G	R	Q	W	F	D	L	R	E	F	N	M	A	
		GGTCGTCAGTGGTTTCGATTGCGT	GAATTC	AAATATGGCA											SEQ ID No: 10
3'		CCAGCAGTCACCAAGCTAAACGCACTTAAGTTATACCGT	5'	5950.SL											SEQ ID No: 9
															SEQ ID No: 8

Figure 18A. Construction of a plasmid containing *T7 hmwB*.



Co-exprn fig 18A
phmwB

Figure 18B. Oligonucleotides for construction of the Hind III-BamH I 3' *hmwB* fragment.

Sequence	SEQ ID No
Hind III	SEQ ID No:13
S L D A F V A R R F A N A N S D N L N G N K K R T S S P T T F W G R L T F S F * *	SEQ ID No:11
AGCTTAGATGCTTTGTTGCTGCTGCTTTGCAATGCCAATAGTCACAATTTGAATGCCACAAAAA	7073.SL
	7074.SL
CGCACAAAGCTCACCTACAACCTTCTCGGGTAGATTACATTCAGTTTCTAATAG	7076.SL
ATCTACGAAACAACGACGACGAGGAAACGTTTACGGTTATCACTGTTAACTTACCGTTGTTTTTTCGGTGTTCCGAG	7075.SL
TGGATGTTGGAAGACCCCATCTAATTGTTAGTCAAGATTATCCTAG	SEQ ID No:14
BamH I	

Figure 19A. Construction of a plasmid containing *T7 hmwC*.




Figure 19B. Oligonucleotide primers for PCR amplification of Nde I-Xho I 5' *hmc* fragment.

coding strand:

		Nde I			
		M T K E N L Q S V P			
5'	GGCCG	CATATG	AACAAAAGAAAATTTACAAAGTGTTCCA	3'	7077.SL
					SEQ ID No:17
					SEQ ID No:16

non-coding strand:

			Xho I		
		S T S M I A A R E K F Y			
		TCAACTTCAATGATTGCTG	CTCGAG	AAAAATTCTAT	
3'	AGTTGAAGTTACTAACGACGAGCTCTTTTAAAGATA			5'	7078.SL
					SEQ ID No:20
					SEQ ID No:19
					SEQ ID No:18

Figure 19C. Oligonucleotides for construction of Hind III-BamH I 3' hmwC fragment.

[illegible]

Docket No.
1038-1026 MIS:jb

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

CO-EXPRESSION OF RECOMBINANT PROTEINS

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International

Application Number _____

and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Michael I. Stewart (24,973)

Send Correspondence to: **Sim & McBurney**
6th Floor, 330 University Avenue
Toronto, Ontario
Canada, M5G 1R7.

Direct Telephone Calls to: *(name and telephone number)*
(416) 595-1155

Full name of sole or first inventor Sheena M. Loosmore	
Sole or first inventor's signature	Date
Residence Aurora, Ontario, Canada	
Citizenship Canadian	
Post Office Address 70 Crawford Rose Drive, Aurora, Ontario, Canada, L4G 4R4.	

Full name of second inventor, if any Yan-Ping Yang	
Second inventor's signature	Date
Residence Toronto, Ontario, Canada	
Citizenship Canadian	
Post Office Address Apt. 1803, 35 Empress Avenue, Toronto, Ontario, Canada, M2N 6T3.	